Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

Advertisement

Related Content

TaiMed's Trogarzo Is US FDA's First HIV/AIDS Breakthrough Approval
Theratechnologies Sets $118k Yearly Price For HIV Biologic Trogarzo
First Three Novel Biologic Suffixes Came Courtesy Of US FDA, Not Sponsors
CNS Treatments Highlight US FDA's Busy Pipeline Of Novel Agents For 2018
Sanofi Sees Cemiplimab As Path To Relevance In Immuno-Oncology
Loxo Sees Larotrectinib As Model Form Of Oncology Drug Development
Keeping Track: Neurology And Breakthroughs Stay In Spotlight As US FDA Approves Radicava, Imfinzi; TaiMed Submits Ibalizumab
Theratechnologies' Novel AIDS Drug Filed In US
Synthetic Biologics Thinks Statins May Get At Root Of IBS-Constipation
FDA May Ease Up On CV Safety Requirements For GI Motility Drugs Compared To Diabetes, Obesity

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122686

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel